Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
BDO backs Atlas takeover

2018-07-16 businessnews.com.au
Hancock Prospecting’s $326 million takeover bid for struggling iron ore miner Atlas Iron has been endorsed by independent expert BDO, which found the pricing was fair and reasonable.
AGO ATLGF AGODY

0
'Fair and reasonable': Rinehart bid for Atlas receives boost

2018-07-16 theage.com.au
The $390 million offer by the Gina Rinehart camp for Atlas Iron has been declared “fair and reasonable” in an independent expert’s report examining the offer for the loss-making junior miner.
AGO FSUMF ATLGF AGODY MALRY FMG MALRF MIN FSUGY

0
'Fair and reasonable': Rinehart bid for Atlas receives boost

2018-07-16 smh.com.au
The $390 million offer by the Gina Rinehart camp for Atlas Iron has been declared “fair and reasonable” in an independent expert’s report examining the offer for the loss-making junior miner.
AGO FSUMF ATLGF AGODY MALRY FMG MALRF MIN FSUGY

0
Atlas Iron urges investors to accept Hancock takeover

2018-07-16 australianmining.com.au
Atlas Iron’s directors have unanimously recommended shareholders accept Hancock Prospecting subsidiary Redstone Corporation’s $390 million takeover offer in a company target statement.
AGO ATLGF AGODY MALRY MALRF MIN

0
An Update On Pilbara Minerals

2018-07-12 seekingalpha
Pilbara Minerals has progressed exceptionally well from when I last wrote on them in May 2017.
PLS PILBF AGO ATLGF AGODY

0
ASIC extends Atlas deadline for Hancock takeover offer response

2018-07-12 australianmining.com.au
The Australian Securities and Investments Commission (ASIC) has granted Atlas Iron relief regarding the deadline of its target statement in response to a $390 million takeover offer from Gina Rinehart-owned Hancock Prospecting.
PLS PILBF AGO ATLGF AGODY MALRY MALRF MIN

0
Gina Rinehart scores big win in war for Atlas Iron

2018-07-02 theage.com.au
The battle for West Australian junior miner Atlas Iron has tipped heavily in Hancock Prospecting's favour after the Takeovers Panel announced it would not conduct an inquiry into its takeover bid.
AGO ATLGF AGODY

0
Gina Rinehart scores big win in war for Atlas Iron

2018-07-02 smh.com.au
The battle for West Australian junior miner Atlas Iron has tipped heavily in Hancock Prospecting's favour after the Takeovers Panel announced it would not conduct an inquiry into its takeover bid.
AGO ATLGF AGODY

0
Gina Rinehart scores big win in war for Atlas Iron

2018-07-02 smh.com.au
The battle for Western Australian junior miner Atlas Iron has tipped heavily in Hancock Prospecting's favour after the Takeovers Panel announced it would not conduct an inquiry into its takeover bid.
AGO ATLGF AGODY

4
Panel dismisses FMG application

2018-07-02 businessnews.com.au
The Takeovers Panel has dismissed an application from Fortescue Metals Group questioning the veracity of Hancock Prospecting’s $390 million bid for Atlas Iron.
AGO FSUMF ATLGF AGODY FMG FSUGY

8
Takeovers Panel clears Hancock bid for Atlas Iron

2018-07-02 australianmining.com.au
The Takeovers Panel will not take action following an application from a Fortescue Metals Group subsidiary to conduct proceedings into the takeover of Atlas Iron.
AGO FSUMF ATLGF AGODY MALRY FMG MALRF MIN FSUGY

4
Hancock Prospecting will run a comb through Atlas

2018-06-30 theage.com.au
Billionaire Gina Rinehart's Hancock Prospecting will conduct a strategic review of Atlas Iron that will include its port arrangements if it successfully acquires the miner, a new bidders statement released on Friday has revealed.
AGO FSUMF ATLGF AGODY FMG FSUGY

4
Hancock Prospecting will run a comb through Atlas

2018-06-30 smh.com.au
Billionaire Gina Rinehart's Hancock Prospecting will conduct a strategic review of Atlas Iron that will include its port arrangements if it successfully acquires the miner, a new bidders statement released on Friday has revealed.
AGO FSUMF ATLGF AGODY FMG FSUGY

33
Deals of the day-Mergers and acquisitions

2018-06-29 reuters
June 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1130 GMT on Friday:
ELM CVG ROP FOX TMO AGODY IX 532843 ELMTY VZA SNX AGO FORTIS ATLGF VZ FOXA DIS

0
Mark my words podcast

2018-06-29 businessnews.com.au
In this Business News podcast Mark Beyer and Mark Pownall discuss defence contracts, Scarborough high rise, Landgate and TAB privatisation, Atlas Iron, 2018's Rising Stars, and our special report on Indigenous business.
AGO ATLGF AGODY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AGO / ATLAS IRON LIMITED on message board site Silicon Investor.

Chicago Bears Fan Club Agouron Pharmaceuticals (AGPH)
NovaGold Resources Inc. (NG) -NYSE MKT Chicago Bridge u0026 Iron Company N.V. (CBI)
CRNT: Ceragon Networks Ltd. NOVAGOLD RESOURCES INC. (TSE:NRI; OTC BB: NVGLF)
DragonflyPicks Dragon Systems, Inc. [DRGN]
PTG: Paragon Technologies Inc. MELu0027S PASSION OF CHRIST EVOKES SYNAGOGUEu0027S LOATHING